Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02654587
Title Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors OSE Immunotherapeutics
Indications

lung non-small cell carcinoma

Therapies

OSE 2101

Pemetrexed Disodium

Docetaxel

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU

Additional content available in CKB BOOST